Biomedical Engineering Core

生物医学工程核心

• 批准号: 10582672
• 负责人: Steven Allan Soper
• 金额: $ 24.5万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-15 至 2024-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10582672
• 关键词: Address; Area; Automation; Basic Science; Biological; Biological Assay; Biological Markers; Biology; Biomedical Engineering; Biotechnology; Blood; Cells; Centers of Research Excellence; Characteristics; Clinical; Communities; Consensus; Consumption; DNA; Data; Data Set; Development; Disease; Disease model; Educational workshop; Faculty; Functional disorder; Funding; Generations; Goals; Hand; Human Resources; Immunoassay; Infrastructure; Injections; Kansas; Lab On A Chip; Laboratories; Malignant Neoplasms; Measurement; Microfluidics; Mission; Molds; Molecular; Mutation Detection; Nature; Neoplasm Circulating Cells; Oncology; Patient-Focused Outcomes; Patients; Performance; Plastics; Process; Production; Proteins; Proteomics; RNA; Reagent; Research Personnel; Resources; Saliva; Sampling; Secure; Services; Structure; System; Technology; Time; Translating; Translational Research; Treatment Protocols; Urine; Validation; Work; biomedical imaging; cell free DNA; circulating biomarkers; clinical translation; commercialization; cost; design; exosome; extracellular vesicles; high volume manufacturing; human disease; improved; in-vitro diagnostics; innovation; liquid biopsy; liquid chromatography mass spectrometry; manufacture; meetings; member; minimally invasive; nanometer; new technology; next generation sequencing; novel therapeutics; precision medicine; prototype; success; tool; web site

Abstract Circulating markers found in accessible samples (blood, saliva, urine, etc.) represent an exciting biomarker class due to the minimally invasive nature of securing them. Potentially, these circulating markers can enable studies directed toward understanding the pathophysiology of a disease and translating those discoveries to the bedside for managing a host of human diseases by matching the molecular characteristics of the disease to proper treatment regimens (i.e., precision medicine). The attractive nature of circulating markers (i.e., liquid biopsy markers) is the plethora of marker types found in the sample such as biological cells, cell-free molecules (proteins and cell-free DNA) and extracellular vesicles (nanometer assemblies such as exosomes). Unfortunately, basic studies and clinical translation of these liquid biopsy markers has been challenging due to the lack of efficient platforms for their isolation that can also accommodate downstream molecular characterization of the circulating marker cargo. KIPM will generate the Biomedical Engineering Core that will provide to COBRE investigators transformative tools, including hardware and the associated assays, that can be programmed for the project at hand and provide to investigators high quality circulating markers to serve as inputs for a variety of molecular characterization assays (DNA/RNA Next Generation Sequencing, proteomics, immunoassays, mutation detection, liquid chromatography/mass spectrometry, and many others). The hardware tools are lab-on-a-chip or microfluidic platforms that have been optimized for the isolation of circulating markers and clinically validated in a variety of application areas. The microfluidic tools also have validated assays and an automated workflow that has been developed by members of the BME Core. These tools have noteworthy performance metrics compared to commercially available products directed for the isolation of circulating markers. The microfluidics are produced in a high scale production mode at low cost because they are made from plastics and formed into the appropriate structures using injection molding, an established production pipeline for producing CDs, DVDs and Blu-Ray discs. Using these tool sets, the BME Core will create a laboratory that can immediately service COBRE investigators on their precision medicine based projects. Due to the unique capabilities of the tools employed by the BME Core, the data sets generated by the KIPM investigators and the unique tools to acquire these data sets will improve their competitiveness in seeking federally-funded support of their projects. For COBRE projects that cannot be effectively serviced by the Core’s existing tools, the Core will work with the project PI to design new tools to accommodate their project that will also add new process capabilities to the BME Core. The BME Core has assay design capabilities and prototyping tools to support this activity.

抽象的 在可获取的样本（血液、唾液、尿液等）中发现的循环标记物是一种令人兴奋的生物标记物 由于保护它们的微创性质，这些循环标记物有可能成为可能。 研究旨在了解疾病的病理生理学并将这些发现转化为 通过匹配疾病的分子特征来治疗多种人类疾病的床边 正确的治疗方案（即精准医疗）。 活检标记）是在样品中发现的大量标记类型，例如生物细胞、无细胞标记 分子（蛋白质和游离 DNA）和细胞外囊泡（纳米组件，例如外泌体）。 不幸的是，这些液体活检标记物的基础研究和临床转化一直具有挑战性，因为 缺乏有效的分离平台，也可以容纳下游分子 KIPM 将生成生物医学工程核心，该核心将 为 COBRE 研究人员提供变革性工具，包括硬件和相关检测，这些工具可以 为手头的项目进行编程，并为研究人员提供高质量的循环标记物，作为 各种分子表征分析（DNA/RNA 下一代测序、蛋白质组学、 免疫分析、突变检测、液相色谱/质谱分析等）。 硬件工具是芯片实验室或微流体平台，已针对分离进行了优化 微流体工具还具有循环标记物并在各种应用领域进行临床验证。 由 BME 核心成员开发的经过验证的检测方法和自动化工作流程。 与针对该领域的商用产品相比，该工具具有值得注意的性能指标 微流体以低成本的大规模生产模式进行分离。 因为它们是由塑料制成并通过注塑成型形成适当的结构， BME 使用这些工具集建立了生产 CD、DVD 和蓝光光盘的生产流程。 Core 将创建一个实验室，可以立即为 COBRE 研究人员提供精准医学服务 由于 BME Core 使用的工具的独特功能，生成的数据集。 由 KIPM 研究人员和获取这些数据集的独特工具将提高他们的竞争力 对于无法有效服务的 COBRE 项目寻求联邦政府资助。 核心现有工具，核心将与项目 PI 合作设计新工具以适应他们的需求 该项目还将为 BME Core 添加新的处理功能 BME Core 具有化验设计。 支持此活动的功能和原型工具。